Top-line results from both trials due in 2014. Data intended to lead to an NDA filing with the FDA in the U.S. Phase 2 dose ranging trial of GWP42004 for the treatment of Type 2 diabetes expected to commence in the second half of 2013; Phase 1 trial of GWP42006 for the treatment of epilepsy expected to commence in the second half of 2013; and Phase ... (more)
http://www.sys-con.com/node/2682330
http://www.sys-con.com/node/2682330
No comments:
Post a Comment